Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy.
Standard
Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy. / Lips, E H; Mulder, L; Hannemann, Juliane; Laddach, N; Vrancken Peeters, M T F D; van de Vijver, M J; Wesseling, J; Nederlof, P M; Rodenhuis, S.
In: ANN ONCOL, Vol. 22, No. 4, 4, 2011, p. 870-876.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy.
AU - Lips, E H
AU - Mulder, L
AU - Hannemann, Juliane
AU - Laddach, N
AU - Vrancken Peeters, M T F D
AU - van de Vijver, M J
AU - Wesseling, J
AU - Nederlof, P M
AU - Rodenhuis, S
PY - 2011
Y1 - 2011
N2 - Tumors with homologous recombination deficiency (HRD), such as BRCA1-associated breast cancers, are not able to reliably repair DNA double-strand breaks (DSBs) and are therefore highly sensitive to both DSB-inducing chemotherapy and poly (ADP-ribose) polymerase inhibitors. We have studied markers that may indicate the presence of HRD in HER2-negative breast cancers and related them to neoadjuvant chemotherapy response.
AB - Tumors with homologous recombination deficiency (HRD), such as BRCA1-associated breast cancers, are not able to reliably repair DNA double-strand breaks (DSBs) and are therefore highly sensitive to both DSB-inducing chemotherapy and poly (ADP-ribose) polymerase inhibitors. We have studied markers that may indicate the presence of HRD in HER2-negative breast cancers and related them to neoadjuvant chemotherapy response.
M3 - SCORING: Journal article
VL - 22
SP - 870
EP - 876
JO - ANN ONCOL
JF - ANN ONCOL
SN - 0923-7534
IS - 4
M1 - 4
ER -